BG Medicine Goes Public, Begins Trading on Nasdaq | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BG Medicine today began trading shares of its stock on the Nasdaq under ticker symbol "BGMD."

The company is offering 5 million shares of its stock at $7 per share, for potential proceeds of $35 million. Lazard Capital Markets is serving as the sole book-running manager for the offering. Baird and Cowen and Company are co-managers.

The underwriters have a 30-day option to purchase up to 750,000 shares to cover over-allotments, if any.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.